Table 1.
Antitumor activity of Goniothalamus species
| Species | Chemical component | Cells | Dose | Cell cycle/apoptosis |
|---|---|---|---|---|
| G. giganteus | 4-Deoxyanomontacin (27) | A-549a | 6.45 × 10−7 μg/ml | |
| MCF-7b | 5.77 × 10−7 μg/ml | |||
| HT-29c | 1.41 × 10−1 μg/ml | |||
| A-498d | 1.50 × 10−1 μg/ml | |||
| PC-3e | 1.73 × 10−1 μg/ml | |||
| PACA-2f | 1.×10−5 μg/ml | |||
| (2,4-cis and trans)- annomontacinone (27) | HT-29 | 2.55 × 10−1 μg/ml | ||
| PACA-2 | 6.78 × 10−1 μg/ml | |||
| cis-Gigantrionenin (32) | A-549 | 5.99 × 10−2 μg/ml | ||
| MCF-7 | 2.68 × 10−1 μg/ml | |||
| HT-29 | 6.94 × 10−6 μg/ml | |||
| A-498 | 1.39 × 10−2 μg/ml | |||
| PC-3 | 1.11 × 10−1 μg/ml | |||
| PACA-2 | 1.15 × 10−1 μg/ml | |||
| 4-Acetylgigantetrocin (25) | A-549 | <10−2 μg/ml | ||
| MCF-7 | 8.5 × 10−1 μg/ml | |||
| HT-29 | <10−2 μg/ml | |||
| A-498 | 1.55 × 10−1 μg/ml | |||
| PACA-2 | <10−2 μg/ml | |||
| Annonacin (19) | PA1g | 0.452 μg/ml | G1 | |
| SKOV3h | 0.411 μg/ml | |||
| HeLai | 0.219 μg/ml | |||
| HeLa S3j | 0.426 μg/ml | |||
| MCF-7 | 0.433 μg/ml | |||
| T-24k | 0.324 μg/ml | |||
| BCC-1l | 0.427 μg/ml | |||
| Gigantransenin A (26) | A-549 | 0.16 μg/ml | ||
| Gigantransenin B (26) | A-549 | 0.21 μg/ml | ||
| MCF-7 | 2.1 × 10−1 μg/ml | |||
| Gigantrasenin C (26) | A-549 | 0.18 μg/ml | ||
| Goniotetrocin (29) | A-549 | 3.9 10−1 μg/ml | ||
| PC-3 | 2.1 10−1 μg/ml | |||
| PACA-2 | 2.6 10−2 μg/ml | |||
| (2,4-cis and trans) | ||||
| Gonioneninone (29) | PACA-2 | 4.5 10−2 μg/ml | ||
| Goniothalamicin (24) | A-549 | 2.8010−1 μg/ml | ||
| Gonionenine (24) | PACA-2 | 4.5 10−1 μg/ml | ||
| Pyranicin (30) | A-549 | 2.8 10−1 μg/ml | ||
| MCF-7 | 3.6 × 10−1 μg/ml | |||
| A-498 | 1.8 × 10−1 μg/ml | |||
| PACA-2 | 1.3 10−3 μg/ml | |||
| Deoxyannomontacin (27) | A-549 | 6.45 10−7 μg/ml | ||
| MCF-7 | 1.41 × 10−1 μg/ml | |||
| A-498 | 1.50 × 10−1 μg/ml | |||
| PACA-2 | 1.5 10−5 μg/ml | |||
| Annomontacinone (27) | HT-29 | 2.55 × 10−1 μg/ml | ||
| G. giganteus | Annomontacinone (27) | PACA-2 | 6.78 × 10−1 μg/ml | |
| Pyragonicin (30) | A-549 | <10−2 μg/ml | ||
| HT-29 | 3.4 10−1 μg/ml | |||
| A-498 | 1.55 × 10−1 μg/ml | |||
| PACA-2 | 5.8 10−3 μg/ml | |||
| Goniotrionin (30) | A-549 | 7.7 10−3 μg/ml | ||
| MCF-7 | 8.5 × 10−1 μg/ml | |||
| MCF-7 | 5.3 10−6 μg/ml | |||
| A-498 | 2.10−3 μg/ml | |||
| PC-3 | 3.6 10−1 μg/ml | |||
| PACA-2 | 5.4 10−3 μg/ml | |||
| G. donnaiensis | Goniodonin (34,35) | HCT-8m | <10 μg/ml | |
| Donhexocin (34,35) | HCT-8 | 0.82 μg/ml | ||
| Donbutocin (34,35) | L1210 | 0.81 μg/ml | ||
| G. gardneri | Gardnerilin A (37) | Bel7402n | 3.6 μg/ml | |
| Gardnerilin B (37) | Bel7402n | 8.5 μg/ml | ||
| G. andersonii | Goniothalamin (47) | HL-60o | apoptosis | |
| Jurkat Tp | apoptosis | |||
| G. griffithii | Goniothalamin (82) | HepG2 | 8.83 μM | G2/apoptosis |
| HepG2R | 8 μM | |||
| Altholactone (82) | HepG2 | 0.7 μM | apoptosis | |
| HepG2R | 6.17 μM | |||
| Goniodiol (82) | HepG2 | 10 μM | G2 | |
| HepG2R | 8.33 μM | |||
| G. malayanus | Altholactone (74,76) | HL60 | apoptosis | |
| G. borneensis | Goniothalamin (49) | P388 | 0.75 μg/ml | |
| WEHI164 | 1.70 μg/ml | |||
| MOLT-4 | <1 μg/ml | |||
| G. howii | Howiinol (79) | L1210 | 6.85 μg/ml | G1 |
| G. cheliensis | Goniolactone B (54) | A2780 | 7.40 μM | |
| HCT-8 | 4.43 μM | |||
| KB | 7.23 μM | |||
| Synthesized | Goniothalamin (66) | MCF-7 | 10.5 μM | |
| HT-29 | 11.2 μM |
ahuman lung carcinoma; bhuman breast carcinoma; chuman colon adenocarcinoma; dhuman kidney carcinoma, ehuman prostate adenocarcinoma, fhuman pancreatic carcinoma, g,hovarian cancer cells; I,jcervical cancer; kbladder cancer; lskin cancer, mhuman colon adenocarcinoma, nhepatoma cell-line, oleukemia cells, ppromyelocytic leukemia cells; qEhrlich ascites tumor cells.